**Supplementary Table 5.** Obesity-related comorbidities/complications and malignancies, along with relative risk and obesity-attributable fraction in Türkiye [9,11,20,21,32,36,39]

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Prevalence** | **New diagnosis, n** | **Total patients, n** | **Relative risk (vs. non-obese)** | | **OAF (**%) | |
| **Male** | **Female** |
| **Cardiovascular diseases** | | | |  | |  |  |
| Ischemic heart disease | 51.7% | 147,620 | 1,143,800 | 2.21 (%95 GA 1.61-3.04; p<0.0001) | | 17.1 | 23.2 |
| Hypertension | 36.1% | 123,263 | 798,705 | 2.38 (%95 GA 2.19-2.59; p<0.0001) | | 14.5 | 25.0 |
| Cerebrovascular disease | 10.9% | 105,277 | 240,191 | 1.55 (%95 GA 1.16-2.07; p=0.0031) | | 4.6 | 6.8 |
| **Endocrine- Metabolic Diseases** | | | |  | |  |  |
| Type 2 diabetes | 23.2% | 35,084 | 513,639 | 3.44 (%95 GA 2.92-4.05; p<0.0001) | |  |  |
| Metabolic Syndrome | 47.8% | 58,272 | 1,056,786 |  | |  |  |
| Hyperlipidemia | 17.7% |  | 390,659 |  | |  |  |
| **Gastrointestinal Diseases** | | | |  | |  |  |
| GERD | 54.5% | 200,110 | 1,205,127 |  | |  |  |
| Gall bladder diseases | 2.4% | 52,305 |  |  | |  |  |
| MAFLD | 10.4% | 229,703 |  |  | |  |  |
| **Musculoskeletal System Disorders** | | | |  | |  |  |
| Chronic low back pain | 45.1% |  | 997,552 |  | |  |  |
| Osteoarthritis | 18.0% | 75,753 | 398,136 | 1.95 (%95 GA 1.85-2.06; p<0.0001) | | 12.5 | 30.9 |
| **Pulmonary System Diseases** | | | |  | |  |  |
| OSAS | 11.9% | 34,328 | 264,060 | 4.69 (%95 GA 2.67-8.24; p<0.0001) | | 40.3 | 49.8 |
| Asthma | 15.0% | 43,889 | 331,780 | 2.01 (%95 GA 1.89-2.13; p<0.0001) | | 6.8 | 21.9 |
| COPD | 13.2% | 37,573 | 291,967 | 1.89 (%95 GA 1.77-2.01; p<0.0001) | | 6.0 | 22.1 |
| Pneumonia | 6.9% | 152,632 |  |  | |  |  |
| Pulmonary embolus | 0.3% | 6,986 |  |  | |  |  |
| **Psychiatric disorders** | | | |  | |  |  |
| Depressive disorder | 18.5% | 408,427 |  | 1.43 (%95 GA 1.34-1.51; p<0.0001) | | 4.0 | 8.2 |
|  | **Incidence, %** | **Age (year)** | | **Relative risk** | | **OAF (%)** | |
| **Male** | **Female** | **Male** | **Female** |
| **Malignancies** |  |  | |  |  |  |  |
| Esophageal cancer | 0.06 | 64.1 | | 2.73 |  | %22.9 | %30.5 |
| Gastric cardia cancer | 0.15 | 64.6 | | 1.61 |  | %9.5 | %13.4 |
| Colorectal cancer | 0.2 | 64.1 | | 1.38 | 1.17 | %6.1 | %4.1 |
| Liver cancer | 0.05 | 65.9 | | 1.83 |  | %12.5 | %17.4 |
| Gall bladder cancer | 0.01 | 66.4 | | 1.54 | 1.75 | %8.5 | %16.0 |
| Pancreas cancer | 0.02 | 66.5 | | 1.20 | 1.15 | %3.3 | %3.7 |
| Post-menopausal breast cancer | 0.4 | 60.6 | |  | 1.28 |  | %6.7 |
| Endometrial cancer | 0.3 | 59.0 | |  | 2.54 |  | %28.1 |
| Ovarian cancer | 0.02 | 57.5 | |  | 1.11 |  | %2.7 |
| Prostate cancer | 0.1 | 68.4 | | 1.1 |  | %1.69 |  |
| Renal cancer | 0.1 | 60.4 | | 1.63 | 1.95 | %9.8 | %19.4 |
| Non-Hodgkin lymphoma | 0.03 | 59.7 | | 1.12 | 1.14 | %2.0 | %3.4 |
| Multiple myeloma | 0.02 | 65.0 | | 1.23 | 1.15 | %3.8 | %3.7 |
| Acute leukemia | 0.1 | 57.3 | | 1.17 | 1.37 | %2.8 | %8.6 |
| Thyroid cancer | 0.2 | 47.8 | | 1.27 |  | %4.4 | %6.4 |
| GERD: Gastroesophageal reflux disease; MAFLD: Metabolic dysfunction associated fatty liver disease; OSAS: Obstructive sleep apnea  syndrome; COPD: Chronic obstructive pulmonary disease; OAF: Obesity-attributable fraction; CI: Confidence interval | | | | | | | |